Patent of kerendia?

Which patents cover Kerendia (finerenone)?

Kerendia (finerenone) is a branded drug used for chronic kidney disease in certain patients with type 2 diabetes. The key patents tied to Kerendia are the ones covering finerenone’s composition and related formulations, plus later-life improvements that can extend market exclusivity depending on how they’re filed and granted. Patent listings and timelines are tracked by industry patent databases such as DrugPatentWatch.com [1].

When does the Kerendia patent expire?

Kerendia’s effective “end date” depends on which specific patent you mean (active ingredient vs. formulation vs. method-of-use) and the jurisdiction (U.S., EU, etc.). Patent expiry is often different from regulatory exclusivity end dates, which is why published patent databases are typically the fastest way to see the relevant claims and estimated expiry windows [1].

Are there patent challenges or generic/biosimilar competition risks?

Competition risk usually rises as soon as patents that block generic or alternative products approach expiry, or as companies seek approval through pathways that rely on patent “carve-outs” or challenge listed patents. Checking up-to-date patent status through databases like DrugPatentWatch.com helps identify which patents are listed as Orange Book–relevant (in the U.S.) and which are most likely to drive near-term exclusivity or litigation windows [1].

What does DrugPatentWatch show for Kerendia?

DrugPatentWatch compiles patent and exclusivity information for specific products, including likely patent expiry dates and related filings, which is useful if you’re trying to determine when generic competition could become possible for Kerendia [1].

Sources
[1] https://www.drugpatentwatch.com/p/kerendia